# EDGAR Filing Document

**Accession Number:** 0001478320
**File Stem:** 0000950170-23-002786
**Filing Date:** 2023-2
**Character Count:** 22369
**Document Hash:** a2387d1324e1b38d31d90e1a72371f86
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-002786.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0000950170-23-002786

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230214

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Adaptive Biotechnologies Corp
- **CENTRAL INDEX KEY:** 0001478320
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 270907024
- **STATE OF INCORPORATION:** WA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38957
- **FILM NUMBER:** 23629495

**BUSINESS ADDRESS:**
- **STREET 1:** 1165 EASTLAKE AVE E
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98109
- **BUSINESS PHONE:** 206-659-0067

**MAIL ADDRESS:**
- **STREET 1:** 1165 EASTLAKE AVE E
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98109

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Adaptive TCR Corp
- **DATE OF NAME CHANGE:** 20091209

?xml version="1.0" encoding="ASCII"? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549** 

------

**FORM** 8-K

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported):** February 14, 2023

------

ADAPTIVE BIOTECHNOLOGIES CORPORATION

**(Exact name of Registrant as Specified in Its Charter)** 

------

---

| | | |
|:---|:---|:---|
| Washington | 001-38957 | 27-0907024 |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |
| 1165 Eastlake Avenue East<br>Seattle**,** Washington |  | 98109 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: (**206**)** 659-0067

**Not Applicable** 

**(Former Name or Former Address, if Changed Since Last Report)** 

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| Common stock, par value $0.0001 per share | ADPT | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02**  | **Results of Operations and Financial Condition.** |

---

On February 14, 2023, Adaptive Biotechnologies Corporation (the "**Company**") issued a press release regarding the Company's financial results for the quarter and fiscal year ended December 31, 2022. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 99.1 | [<u>Press Release dated February 14, 2023</u>](adpt-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Adaptive Biotechnologies Corporation** | **Adaptive Biotechnologies Corporation** |
| Date: February 14, 2023 | By: | /s/ Tycho Peterson |
|  |  | Tycho Peterson |
|  |  | Chief Financial Officer |

---

------

## Ex-99

EXHIBIT 99.1

![img119828894_0.jpg](img119828894_0.jpg)

**Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results** 

**SEATTLE, Feb. 14, 2023 (GLOBE NEWSWIRE)** – Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2022.

"We finished the year with 20% revenue growth, driven by both our MRD and Immune Medicine business areas," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "2023 has started strong and I am encouraged to see how momentum is building. We are growing revenue, advancing our pipeline and managing operating expenses with the capital to fuel sustainable growth and execute towards our goals."

**Recent Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Revenue of $55.2 million for the fourth quarter and $185.3 million for the full year of 2022, representing a 46% increase and 20% increase over the corresponding periods in 2021, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•clonoSEQ test volume increased 54% to 10,526 tests delivered in the fourth quarter of 2022, compared to the fourth quarter 2021 and ended the year with 36,871 tests delivered, up 51% versus 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Launched clonoSEQ to assess MRD in patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin's lymphoma, with Medicare coverage.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Delivered 2 additional TCR data packages to Genentech.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Strengthened our capital position, ending the year with $498.2 million in cash, cash equivalents and marketable securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Provided long-term guidance including a 20%-30% revenue CAGR, positive adjusted EBITDA in 2025 and cash flow breakeven in 2026.

**Fourth Quarter 2022 Financial Results**

Revenue was $55.2 million for the quarter ended December 31, 2022, representing a 46% increase from the fourth quarter in the prior year. Immune Medicine revenue was $27.1 million for the quarter, representing a 27% increase from the fourth quarter in the prior year. MRD revenue was $28.1 million for the quarter, representing a 70% increase from the fourth quarter in the prior year.

Operating expenses were $94.4 million for the fourth quarter of 2022, compared to $99.5 million in the fourth quarter of the prior year, representing a decrease of 5%. Interest expense from our revenue interest purchase agreement was $3.6 million in the fourth quarter of 2022.

Net loss was $40.2 million for the fourth quarter of 2022, compared to $61.4 million for the same period in 2021.

------

Adjusted EBITDA (non-GAAP) was a loss of $19.6 million for the fourth quarter of 2022, compared to a loss of $44.9 million for the fourth quarter of the prior year.

**Full Year 2022 Financial Results**

Revenue was $185.3 million for the year ended December 31, 2022, representing a 20% increase from the prior year. Immune Medicine revenue was $98.2 million in 2022, representing an 11% increase from 2021. MRD revenue was $87.1 million in 2022, representing a 32% increase from the prior year.

Operating expenses for 2022 were $385.5 million, compared to $363.3 million for 2021, representing an increase of 6%. Interest expense from our revenue interest purchase agreement was $4.2 million in 2022.

Net loss was $200.4 million in 2022, compared to $207.3 million in 2021.

Adjusted EBITDA (non-GAAP) was a loss of $121.6 million for 2022, compared to a loss of $151.7 million in the prior year.

Cash, cash equivalents and marketable securities was $498.2 million as of December 31, 2022.

**2023 Financial Guidance**

Adaptive Biotechnologies expects full year 2023 revenue to be in the range of $205 million to $215 million.

We expect operating expenses, including cost of revenue, to be below full year 2022 operating expenses of $385.5 million.

Management will provide further details on the 2023 outlook during the conference call.

**Webcast and Conference Call Information**

Adaptive Biotechnologies will host a conference call to discuss its fourth quarter and full year 2022 financial results after market close on Tuesday, February 14, 2023 at 4:30 PM Eastern Time. The conference call can be accessed at http://investors.adaptivebiotech.com. The webcast will be archived and available for replay at least 90 days after the event.

**About Adaptive Biotechnologies**

Adaptive Biotechnologies ("we" or "our") is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

------

**Forward-Looking Statements**

This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

**Use of Non-GAAP Financial Measure**

To supplement our unaudited consolidated statements of operations and unaudited consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America ("GAAP"), this press release also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, interest expense, income tax (expense) benefit, depreciation and amortization expense, restructuring expense and share-based compensation expense. We have provided a reconciliation of net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.

Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.

Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA does not reflect:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•all expenditures or future requirements for capital expenditures or contractual commitments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•changes in our working capital needs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•interest expense, which is an ongoing element of our costs to operate;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•income tax (expense) benefit, which may be a necessary element of our costs and ability to operate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the noncash component of employee compensation expense; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, such as our March 2022 restructuring and reduction in workforce.

In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries.

**ADAPTIVE MEDIA**<br>Erica Jones, Associate Director, Product Communications

206-279-2423<br><u>media@adaptivebiotech.com</u>

**ADAPTIVE INVESTORS**<br>Karina Calzadilla, Vice President, Investor Relations

201-396-1687<br>investors@adaptivebiotech.com

------

**Adaptive Biotechnologies**

Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Revenue | $55198 | $37930 | $185308 | $154344 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cost of revenue | 16589 | 14356 | 57909 | 49301 |
| &nbsp;&nbsp;&nbsp;Research and development | 31222 | 34699 | 141756 | 142343 |
| &nbsp;&nbsp;&nbsp;Sales and marketing | 23716 | 26696 | 95603 | 95465 |
| &nbsp;&nbsp;&nbsp;General and administrative | 22428 | 23346 | 88527 | 74502 |
| &nbsp;&nbsp;&nbsp;Amortization of intangible assets | 429 | 429 | 1699 | 1699 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 94384 | 99526 | 385494 | 363310 |
| Loss from operations | (39186) | (61596) | (200186) | (208966) |
| Interest and other income, net | 2602 | 239 | 4056 | 1668 |
| Interest expense | (3585) |  | (4238) |  |
| Net loss | (40169) | (61357) | (200368) | (207298) |
| &nbsp;&nbsp;&nbsp;Add: Net loss attributable to noncontrolling interest | 41 | (76) | 177 | 19 |
| Net loss attributable to Adaptive Biotechnologies Corporation | $(40128) | $(61433) | $(200191) | $(207279) |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted | $(0.28) | $(0.43) | $(1.40) | $(1.48) |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted | 143054722 | 141228918 | 142515917 | 140354915 |

---

------

**Adaptive Biotechnologies**

Consolidated Balance Sheets<br>(in thousands, except share and per share amounts)

(unaudited)

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **December 31,** |
|  | **2022** | **2021** |
| **Assets** |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $90030 | $139065 |
| &nbsp;&nbsp;&nbsp;Short-term marketable securities (amortized cost of $412,282 and $214,115, respectively) | 408166 | 213996 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net | 40057 | 17409 |
| &nbsp;&nbsp;&nbsp;Inventory | 14453 | 19263 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 9440 | 13015 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 562146 | 402748 |
| Long-term assets |  |  |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 83447 | 85262 |
| &nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 80763 | 87678 |
| &nbsp;&nbsp;&nbsp;Long-term marketable securities (amortized cost of $218,163) |  | 217145 |
| &nbsp;&nbsp;&nbsp;Restricted cash | 2398 | 2138 |
| &nbsp;&nbsp;&nbsp;Intangible assets, net | 6827 | 8526 |
| &nbsp;&nbsp;&nbsp;Goodwill | 118972 | 118972 |
| &nbsp;&nbsp;&nbsp;Other assets | 2064 | 875 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $856617 | $923344 |
| **Liabilities and shareholders' equity** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $8084 | $3307 |
| &nbsp;&nbsp;&nbsp;Accrued liabilities | 12424 | 9343 |
| &nbsp;&nbsp;&nbsp;Accrued compensation and benefits | 15935 | 15642 |
| &nbsp;&nbsp;&nbsp;Current portion of operating lease liabilities | 9230 | 5055 |
| &nbsp;&nbsp;&nbsp;Current portion of deferred revenue | 64115 | 80460 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 109788 | 113807 |
| Long-term liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities, less current portion | 98772 | 106685 |
| &nbsp;&nbsp;&nbsp;Deferred revenue, less current portion | 58599 | 98750 |
| &nbsp;&nbsp;&nbsp;Revenue interest liability, net | 125360 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 392519 | 319242 |
| Commitments and contingencies |  |  |
| Shareholders' equity |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021 |  |  |
| &nbsp;&nbsp;&nbsp;Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2022 and 2021; 143,105,002 and 141,393,865 shares issued and outstanding at December 31, 2022 and 2021, respectively | 14 | 14 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 1387349 | 1324006 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (4116) | (1137) |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (919082) | (718891) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Adaptive Biotechnologies Corporation shareholders' equity | 464165 | 603992 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interest | (67) | 110 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 464098 | 604102 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and shareholders' equity | $856617 | $923344 |

---

------

**Adjusted EBITDA** 

The following table sets forth a reconciliation between our Adjusted EBITDA and net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, for each of the periods presented (in thousands, unaudited):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Net loss attributable to Adaptive Biotechnologies Corporation | $(40128) | $(61433) | $(200191) | $(207279) |
| Interest and other income, net | (2602) | (239) | (4056) | (1668) |
| Interest expense | 3585 |  | 4238 |  |
| Depreciation and amortization expense | 5286 | 4849 | 20920 | 13953 |
| Restructuring expense |  |  | 2023 |  |
| Share-based compensation expense | 14294 | 11875 | 55477 | 43251 |
| &nbsp;&nbsp;&nbsp;Adjusted EBITDA | $(19565) | $(44948) | $(121589) | $(151743) |

---

------